Compare CFND & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFND | KTTA |
|---|---|---|
| Founded | N/A | 2020 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.4M | 18.1M |
| IPO Year | 2024 | 2021 |
| Metric | CFND | KTTA |
|---|---|---|
| Price | $3.00 | $0.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 82.8K | ★ 165.6K |
| Earning Date | N/A | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $486,559.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3130.37 |
| 52 Week Low | $2.04 | $0.28 |
| 52 Week High | $8.64 | $2.06 |
| Indicator | CFND | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 49.24 | 43.52 |
| Support Level | $2.81 | $0.48 |
| Resistance Level | $3.48 | $0.52 |
| Average True Range (ATR) | 0.16 | 0.03 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 38.09 | 41.84 |
C1 Fund Inc is a non-diversified, closed-end management investment company. The Adviser provides day-to-day investment management services to the Company, which is classified as non-diversified under the Investment Company Act. The Company's investment objective is to maximize its portfolio's total return by principally investing in privately held equity and equity-linked securities of digital asset services and technology companies. Its investments in equity securities include common and preferred shares, securities convertible into common shares, warrants and rights to subscribe to or purchase common shares, and common shares carrying a warrant or right.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.